Rivaroxaban, a factor Xa inhibitor, is now FDA approved for stroke prophylaxis in non-valvular atrial fibrillation. Rivaroxaban is marketed as Xaletro and has previously been approved for post operative DVT prophylaxis after knee or hip surgery.
The Rocket AF trial (industry sponsered and published in NEJM) showed non-inferiority in stroke prophylaxis compared to warfarin. I have previously posted about treating life threatening bleeding in patients on rivaroxaban. Rivaroxaban is a factor Xa inhibitor, and bleeding can be treated with prothrombin complex concentrate which contains Xa.
Add rivaroxaban to your list of drugs that can cause and exacerbate bleeding, and remember to look for rivaroxaban or Xaletro on the meds list of patients with trauma, and especially minor head trauma.